New guidance provides clarity on endpoints, will help spur pharmaceutical innovation for Alzheimer’s treatments NEW YORK, NY (17 May 2018) – The Global Coalition on Aging (GCOA) today submitted comments to the U.S. Food & Drug Administration (FDA) supporting the administration’s new regulatory guidance document on early Alzheimer’s disease and calling for similar updates for related dementias….